{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T06:23:10Z","timestamp":1769062990324,"version":"3.49.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Pheochromocytoma (PCC) and paraganglioma (PGL) (PPGL) are rare neuroendocrine tumors, and data on managing these conditions in children and adolescents are lacking. The objective of this study was to demonstrate the clinical presentation and treatment outcomes in children and adolescents with PPGL in a single tertiary care center in Korea.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective study included 23 patients diagnosed with PCC (<jats:italic>n<\/jats:italic> = 14) and PGL (<jats:italic>n<\/jats:italic> = 9) before the age of 21 at Samsung Medical Center (from June 1994 to June 2019). We describe age, gender, family history, clinical characteristics, laboratory findings, pathologic findings, therapeutic approaches, and treatment outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 23 patients, 14 had PCC and nine had PGL. The median age at diagnosis was 16.8 years (range, 6.8\u201320.8 years). The common presenting symptoms were hypertension (<jats:italic>n<\/jats:italic> = 10), headache (<jats:italic>n<\/jats:italic> = 9), palpitation (<jats:italic>n<\/jats:italic> = 4), and sweating (<jats:italic>n<\/jats:italic> = 4). The plasma or 24-hour urine catecholamine and\/or metabolite concentrations were markedly elevated in 22 patients with PPGL, but were normal in one patient with carotid body PGL. All tumors were visualized on computed tomography. Genetic tests were performed in 15 patients, and seven patients showed mutations in <jats:italic>RET<\/jats:italic> (<jats:italic>n<\/jats:italic> = 3), <jats:italic>SDHB<\/jats:italic> (<jats:italic>n<\/jats:italic> = 3), and <jats:italic>VHL<\/jats:italic> (<jats:italic>n<\/jats:italic> = 1). All patients underwent surgery, and complete excision was performed successfully. Three patients with metastasis underwent postoperative adjuvant therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study suggests that pediatric PPGL tends to be extra-adrenal and bilateral and shows a higher potential for genetic mutations. Considering the hereditary predisposition of pediatric PPGL, genetic screening tests are strongly recommended, and lifelong follow-up is needed to detect recurrence and metastasis. Further research with a larger sample size and routine genetic screening is needed to better understand the genetic conditions and long-term prognosis of PPGL.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2020.610746","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T14:03:35Z","timestamp":1611929015000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Clinical Presentation and Treatment Outcomes of Children and Adolescents With Pheochromocytoma and Paraganglioma in a Single Center in Korea"],"prefix":"10.3389","volume":"11","author":[{"given":"Hyojung","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Sun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiwon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Han","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byong Chang","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanghoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suk-Koo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Yoon","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Kyu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,1,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2017.00155","article-title":"Review of Pediatric Pheochromocytoma and Paraganglioma","volume":"5","author":"Bholah","year":"2017","journal-title":"Front Pediatr"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1806651","article-title":"Pheochromocytoma and Paraganglioma","volume":"381","author":"Neumann","year":"2019","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1353.003","article-title":"Characteristics of pheochromocytoma in a 4- to 20-year-old population","volume":"1073","author":"Barontini","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1053\/jpsu.2001.21612","article-title":"Pheochromocytoma in children","volume":"36","author":"Ciftci","year":"2001","journal-title":"J Pediatr Surg"},{"key":"B5","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/s0094-0143(05)70088-4","article-title":"Pheochromocytoma. Special considerations in children","volume":"27","author":"Ross","year":"2000","journal-title":"Urol Clin North Am"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2005-2299","article-title":"Pheochromocytoma and paraganglioma in children: a review of medical and surgical management at a tertiary care center","volume":"118","author":"Pham","year":"2006","journal-title":"Pediatrics"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/ped.12664","article-title":"Pediatric patients with pheochromocytoma: Experience of a tertiary health center","volume":"57","author":"Eren","year":"2015","journal-title":"Pediatr Int"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/mou.0000000000000650","article-title":"Pediatric pheochromocytoma: current status of diagnostic imaging and treatment procedures","volume":"29","author":"Peard","year":"2019","journal-title":"Curr Opin Urol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(05)67139-5","article-title":"Phaeochromocytoma","volume":"366","author":"Lenders","year":"2005","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaa039","article-title":"Pheochromocytoma and Paraganglioma in Children and Adolescents: Experience of the French Society of Pediatric Oncology (SFCE)","volume":"4","author":"de Tersant","year":"2020","journal-title":"J Endocr Soc"},{"key":"B11","article-title":"Pheochromocytoma and Paraganglioma Treatment (PDQ\u00ae): Health Professional Version","volume-title":"PDQ Cancer Information Summaries","year":"2002"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1677\/erc-07-0074","article-title":"The diagnosis and management of malignant phaeochromocytoma and paraganglioma","volume":"14","author":"Chrisoulidou","year":"2007","journal-title":"Endocr Relat Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-16-0033","article-title":"European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma","volume":"174","author":"Plouin","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-017-9484-5","article-title":"Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours","volume":"28","author":"Lam","year":"2017","journal-title":"Endocr Pathol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13252","article-title":"Is there an optimal preoperative management strategy for phaeochromocytoma\/paraganglioma","volume":"86","author":"Challis","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13284","article-title":"Preoperative alpha-blockade in phaeochromocytoma and paraganglioma: is it always necessary","volume":"86","author":"Isaacs","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-012-0246-y","article-title":"Screening for pheochromocytomas and paragangliomas","volume":"14","author":"Eisenhofer","year":"2012","journal-title":"Curr Hypertens Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2015.08.006","article-title":"Pheochromocytoma and Paraganglioma: Diagnosis, Genetics, and Treatment","volume":"25","author":"Kiernan","year":"2016","journal-title":"Surg Oncol Clin N Am"},{"key":"B19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1159\/000074659","article-title":"Biochemical diagnosis of pheochromocytoma","volume":"31","author":"Eisenhofer","year":"2004","journal-title":"Front Horm Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.21037\/gs.2019.10.25","article-title":"Pheochromocytoma\/paraganglioma: recent updates in genetics, biochemistry, immunohistochemistry, metabolomics, imaging and therapeutic options","volume":"9","author":"Antonio","year":"2020","journal-title":"Gland Surg"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e3181ebb4f0","article-title":"The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer","volume":"39","author":"Chen","year":"2010","journal-title":"Pancreas"},{"key":"B22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1530\/erc-13-0415","article-title":"Long-term prognosis of patients with pediatric pheochromocytoma","volume":"21","author":"Bausch","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020152","article-title":"Germ-line mutations in nonsyndromic pheochromocytoma","volume":"346","author":"Neumann","year":"2002","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.3390\/cancers11081070","article-title":"Pheochromocytomas and Paragangliomas: New Developments with Regard to Classification, Genetics, and Cell of Origin","volume":"11","author":"Koopman","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1136\/adc.2008.139121","article-title":"Phaeochromocytoma in children","volume":"93","author":"Armstrong","year":"2008","journal-title":"Arch Dis Child"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2830","article-title":"A current review of the etiology, diagnosis, and treatment of pediatric pheochromocytoma and paraganglioma","volume":"95","author":"Waguespack","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2478\/enr-2019-0020","article-title":"Pheochromocytoma","volume":"53","author":"Farrugia","year":"2019","journal-title":"Endocr Regul"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.IJEM_558_16","article-title":"Characteristics of Pediatric Pheochromocytoma\/paraganglioma","volume":"21","author":"Sarathi","year":"2017","journal-title":"Indian J Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-3829","article-title":"Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas","volume":"102","author":"Pamporaki","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B30","volume-title":"Tietz textbook of clinical chemistry and molecular diagnostics","author":"Burtis","year":"2012"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2020.610746\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T14:03:38Z","timestamp":1611929018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2020.610746\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,29]]},"references-count":30,"alternative-id":["10.3389\/fendo.2020.610746"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2020.610746","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,29]]},"article-number":"610746"}}